歡迎來到 ... IEHRI 嶄新生態及健康科技研究院

吕禮全 博士/教授/院士

Prof. Dr. LOUIS L.C. LUI  

院長  Executive Director

IEHRI 嶄新生態及健康科技研究院

IEHRI Innovative Ecological and Health Research Institute

The IEHRI Institute and the EAS European Academy of Sciences strive to establish close Sino-EU cooperation in the research and development and promotion of the "State-of-the-art Health Technology"

IEHRI 研究院 聯合 EAS歐洲科學院  努力建立 "先進健康科技" 研究與發展的 中歐緊密合作關系。 

Jointly development of healthcare and skincare applications through biotechnology and genetic engineering with scholar of the Hong Kong University of Science and Technology 

與香港科技大學 (HKUST) 學者合作，透過生物科技及基因工程，共同發展醫療及護膚方案。 

人體表皮生長因子   

Human Epidermal Growth Factor (hEGF)

堿性成纖維細胞生長因子 

 Basic Fibroblast Growth Factor (bFGF) 

Kyoto Pharmaceutical University of Japan is leading in Lipopolysaccharides (LPS) technology research & development and commercialization.  

When LPS is released from bacteria (for example, during bacterial cell death or by the action of antibiotics), it can act as a potent immune system stimulant. The presence of LPS in the bloodstream can trigger a strong immune response, leading to the production of pro-inflammatory cytokines. This immune response is part of the host defense mechanism against bacterial infections.

Research on LPS has been significant in the study of immune system function and the development of therapeutic approaches for conditions involving dysregulated immune responses.

日本京都制药大学 在脂多糖 (LPS) 技术研发和商业化方面处于领先地位.

脂多糖（Lipopolysaccharides，簡稱LPS）是由脂質和多糖組成的大分子，主要存在於革蘭氏陰性細菌的外膜中，包括大腸桿菌（Escherichia coli）、沙門氏菌（Salmonella）和假單胞菌（Pseudomonas）等病原菌。 當LPS從細菌中釋放時（例如，在細菌細胞死亡期間或通過抗生素的作用），它可以充當強效的免疫系統興奮劑。 血流中LPS的存在可引發強烈的免疫應答，導致促炎細胞因子的産生。 這種免疫應答是針對細菌感染的宿主防禦機制的一部分。

利用 LPS的研究 在免疫系統功能的研究和涉及免疫應答失調的病症的治療方法的發展方面具有重要意義。